Capricor Q2 net loss $7.1M; CAP-1002 Phase 3 trial underway, cash $51.4M

CAPRICOR THERAPEUTICS, INC.

2022-Q2 EPS reported -$0.61

Net loss $7.1M ($0.29/share) vs $4.7M ($0.21/share) in Q2 2021.
Cash & equivalents $51.4M at June 30, 2022, up from $34.9M at Dec. 31, 2021.
First patient dosed in HOPE-3 pivotal Phase 3 trial of CAP-1002 for late-stage Duchenne muscular dystrophy.
Positive one-year HOPE-2 OLE data showed statistically significant skeletal muscle improvement (PUL v2.0, p=0.02).
Requesting FDA meeting to discuss CAP-1002 approval pathway; cash runway into Q2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.